Ou H.-Y.Karnchanasorn R.LEE-MING CHUANGChiu K.C.2020-06-012020-06-0120150149-5992https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962437302&doi=10.2337%2fdc15-1700&partnerID=40&md5=f096c0ff78b547a4544a325b6029712bhttps://scholars.lib.ntu.edu.tw/handle/123456789/495574[SDGs]SDG3C peptide; canagliflozin; glucose; antidiabetic agent; canagliflozin; acidosis; autoimmune disease; B lymphocyte; clinical feature; diabetic ketoacidosis; disease association; glucose blood level; health program; human; hyperglycemia; non insulin dependent diabetes mellitus; Note; patient care; risk factor; United States; chemically induced; Diabetes Mellitus, Type 2; diabetic ketoacidosis; female; male; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Humans; Hypoglycemic Agents; Malenote10.2337/dc15-1700264948202-s2.0-84962437302